Melbourne's Peter MacCallum Cancer Centre has reported a new therapy — described as a “genetic blueprint” approach — that achieved a reported 95% long-term remission rate in treated patients by targeting dormant cells that drove recurrences.
Oncologists are cautiously using the word “cure” for some early-stage cases, and regulators expect global fast-track consideration by the end of 2026.
Global Impact: Projected Drop In Ovarian-Cancer Mortality
A 2026 analysis by the Global Oncology Report estimated that the Melbourne protocol could cut projected worldwide ovarian-cancer mortality by roughly 40%. Clinicians called it one of the most significant leaps in gynecological oncology since chemotherapy's introduction.
